Investment Date
December 2012
Vertical
Healthcare
Fund
GCP III
Investment Status
Prior
Visit Website

Therakos

Develops and markets a extracorporeal photopheresis system (ECP), or immune modulation therapy

Highlights
  • Global leader in advancing the science of ECP immune modulation therapy
  • THERAKOSĀ® Photopheresis Systems are the only regulatory approved integrated systems for extracorporeal photopheresis
  • Demonstrated track record of efficacy and safety
  • Used in more than 1,000,000 treatments since initial regulatory approval
  • Headquartered in West Chester, Pennsylvania
  • Carve out from Ortho Clinical Diagnostics, a division of J&J (NYSE: JNJ)
  • Gores sells Therakos to Mallinckrodt Pharmaceuticals (NYSE: MNK) in transaction valued at $1.325 billion